RHB analyst Jarick Seet has downgraded his call on medical oncology and stem cell services provider TalkMed to “hold” from his previous “buy” call. His move comes as international medical tourists – which forms the bulk of TalkMed’s patients – takes a hit from the ongoing travel restri...

SINGAPORE (Apr 1): RHB is keeping its “buy” recommendation on TalkMed with a lowered target price of 53 cents from 62 cents previously. With the ongoing travel restrictions in place due to the Covid-19 outbreak, TalkMed will be seeing a drop in the number of medical tourists, as international v...

SINGAPORE (Feb 17): Medical oncology and stem cell services provider TalkMed Group saw its earnings jump 20.7% to $11.6 million for 4QFY2019 ended December, from $9.6 million a year ago. Earnings per share climbed to 0.88 cent in 4QFY2019, compared to 0.73 cent for 4QFY2018. This brings full year e...

TALKMED on Monday posted a fourth-quarter net profit of S$10.9 million, up 18.9 per cent from the same period a year earlier on a higher number of patient visits.

TALKMED Group on Tuesday posted a net profit of S$9.59 million for the fourth quarter ended Dec 31, up 16.4 per cent from a year ago, on the back of higher revenue and a decrease in the share of loss of associate Hong Kong Integrated Oncology Centre Holdings Limited.

SINGAPORE (Feb 19): TalkMed Group posted a 16.4% increase in earnings to $9.6 million for the 4Q18 ended December, from $8.2 million a year ago. However, the improved 4Q failed to stop the private healthcare services provider from registering a 9.8% decline in earnings for the full year. TalkMed sa...